The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Share News (CSRT)

  • There is currently no data for CSRT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: LSE Up After Merger Bid From Hong Kong Rival

Wed, 11th Sep 2019 10:27

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.

----------

FTSE 100 - WINNERS

----------

London Stock Exchange, up 5.5% at 7,180.00 pence. The operator of the Hong Kong Stock Exchange has made a GBP30 billion offer to buy the London stock exchange operator. Hong Kong Exchanges & Clearing said it will pay 2,045 pence in cash and 2.495 new HKEX shares for each LSEG share, valuing LSEG at GBP29.6 billion. It gives an enterprise value, which includes debt, of GBP31.6 billion. This price, HKEX said, is a 23% premium to LSEG's 6,804.00p closing price in London on Tuesday. HKEX said LSEG's current management would continue to run the business, and HKEX has begun talking with all relevant regulators. HKEX would carry out a secondary listing on the London Stock Exchange as part of the deal. LSE shares hit an intraday high of 7,922p in the wake of the announcement.

----------

FTSE 100 - LOSERS

----------

Royal Dutch Shell 'A' and Shell 'B', down 0.3%. HSBC downgraded the oil major to Hold from Buy.

----------

FTSE 250 - WINNERS

----------

Galliford Try, up 1.3%. The construction and housebuilding company's shares were up despite saying earnings in the most recently ended financial year were hurt by contract write-downs and restructuring. As a result, pretax profit declined 27% to GBP104.7 million from GBP143.7 million year-on-year. Exceptional costs rose to GBP50.8 million from GBP45.0 million due to charges against legacy contracts and restructuring within the Construction business. Galliford Try said its Construction unit performed "well" during the year but there were challenges with some ongoing projects. Elsewhere, Linden Homes delivered steady sales and strong margins in tougher conditions, the company noted, while Partnerships & Regeneration delivered "impressive" growth and increased profitability. The company reduced its annual payout to 58.0 pence a share from 77.0p paid the year before. On Tuesday, housebuilder Bovis Homes said it was in talks to buy Galliford Try's housebuilding business for more than GBP1 billion. Bovis was up 2.8%.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Capital & Regional, up 11%. Johannesburg-listed real estate investment trust Growthpoint Properties confirmed it is in talks with Capital & Regional to acquire a majority stake through a partial offer. The offer would be a combination of cash for Capital & Regional shares, and an injection of capital through a subscription for new shares in the company. Growthpoint has until 1700 BST on October 9 to make a firm offer for the Capital & Regional stake, with both companies stressing that there was no guarantee that any offer will be made. In addition, Capital & Regional reported a pretax loss of GBP55.4 million for the six months to the end of June, compared to a profit of GBP6.7 million the year before. This was on net rental income that dipped by 3.7% to GBP25.2 million from GBP26.0 million, and revenue that declined 0.6% to GBP45.2 million from GBP45.5 million.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Consort Medical, down 3.5%. The medical device manufacturer said full-year profit could be hurt by up to GBP9.0 million, following an incident at a company facility in Northumberland. In July, Consort reported a small area of the operating plant at the Cramlington manufacturing facility was damaged by the "rapid" thermal degradation of chemicals, leading to an "expulsion of material" and contamination. The impact on operating profit for its year ending April 2020 is forecast to be between GBP7.0 million and GBP9.0 million, though this does not factor in any amounts it could recover from its insurance policies. In July, when the accident happened, Consort Medical guided for a GBP3 million to GBP5 million hit on profit. Decontamination took longer than planned but the company said it is "progressing the investigation" to find the root cause of the incident. Excluding the costs of the incident, Consort said underlying performance was in line with full-year expectations.

----------

More News
3 Jan 2017 08:10

Consort Medical splutters as BAT stubs out Voke programme

(ShareCast News) - British American Tobacco has terminated an agreement with Consort Medical over the manufacture of nicotine inhalers for its Voke development programme. Consort, which said it was in "constructive dialogue" with BAT's Nicovations arm and product developer Kind Consumer over the fut

Read more
6 Dec 2016 08:18

Consort Medical posts good growth in first half

(ShareCast News) - Single source drug and delivery device company Consort Medical announced its interim results for the six months to 31 October on Tuesday. The London-listed firm said group revenue increased to £144.9m from £135.5m, representing underlying growth of 2.0% and reported growth of 6.9%

Read more
25 Nov 2016 09:07

Consort Medical appoints new CFO

(ShareCast News) - Consort Medical, a global provider of manufacturing solutions for drugs, announced that it has appointed Paul Hayes as group Finance Director of the Vitec Group. Hayes is taking over the position of chief financial officer from Richard Cotton as well joining the board as executive

Read more
27 Oct 2016 07:45

Consort Medical Welcomes Cimzia Autoclicks Launch On NHS

Read more
14 Oct 2016 12:23

Consort Medical's Bespak inks new agreement

(ShareCast News) - Consort medical, a global single source drug and Delivery device company (CDMO), has announced that its Bespak division has entered into an agreement with a biopharmaceutical company. Bespak manufactures drug delivery devices for pharmaceutical partner companies including respirat

Read more
19 Sep 2016 09:07

Consort Notes European Nod For Bespak Technology-Using Product

Read more
7 Sep 2016 08:43

Consort Medical signs agreement with AstraZeneca

(ShareCast News) - Consort medical, a provider of advanced technology for drugs, has signed a new contract with pharmaceutical giant AstraZeneca for the supply of its Bespak respiratory devices. AstraZeneca and Bespak have agreed to enter into a multi-year agreement for the scale-up and supply of Be

Read more
7 Sep 2016 07:03

Consort Medical Sees Little Brexit Impact; Signs Deal With AstraZeneca

Read more
23 Jun 2016 15:19

Director dealings: Derwent London CEO sells just ahead of Brexit vote

(ShareCast News) - Derwent London chief executive John Burns has sold £1.5m of the FTSE 250 real estate investor's shares in the week just before the EU referendum which could seriously lift or undermine the company's shares. In Wednesday's sale, which comes two days before results for Britain's ref

Read more
17 Jun 2016 09:29

Numis places Consort Medical 'under review'

(ShareCast News) - Consort Medical's shares were put 'under review' by Numis after the company reported its full year results. The pharmaceutical device frim on Thursday reported full year earnings before interest and tax rose 47.6% to £37m as revenues gained 49.8% to £276.9m, driven by a strong per

Read more
16 Jun 2016 14:52

Consort Medical's annual revenues rise as a product launch is delayed

(ShareCast News) - Consort Medical, a pharmaceutical device company, revealed higher full year profits on Thursday due to organic growth and an acquisition. Revenues rose 49.8% to £276.9m from £184.8m the previous financial year. Bespak, the company's drug device manufacturing subsidiary, continued

Read more
16 Jun 2016 07:37

Consort Medical Profit Doubles As Progress Made On DEV610 Programme

Read more
9 Jun 2016 15:04

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
5 Apr 2016 08:32

BROKER RATINGS SUMMARY: Liberum Upgrades Babcock To Hold From Sell

Read more
22 Feb 2016 16:51

Consort Medical agrees partnership and invests in Precision Ocular

(ShareCast News) - Consort Medical has made a £3.3m equity investment for a 13.7% stake in retinal therapeutics specialist Precision Ocular and agreed a development and manufacturing partnership. London-based Precision Ocular has developed retinal treatments that are designed to access specific sma

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.